Company Applies to Legally Mass-Produce Controlled Drugs
Published Date: 11/26/2025
Notice
Summary
Irvine Labs Inc. wants to make large amounts of some powerful, tightly controlled drugs like psilocybin and LSD for research. People and companies involved with these drugs can share their thoughts or ask for a hearing by January 26, 2026. This move could boost scientific studies but also means careful government oversight and no quick cash changes for now.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Application to Manufacture Schedule I Drugs
On October 29, 2025, Irvine Labs Inc. applied to be registered as a bulk manufacturer for several Schedule I substances, including ibogaine, lysergic acid diethylamide (LSD), mescaline, peyote, diethyltryptamine (DET), dimethyltryptamine (DMT), psilocybin, and psilocyn. The company says it plans to manufacture these drugs in bulk for research and development and to distribute them to its research customers.
Comment and Hearing Deadline
Registered bulk manufacturers of the affected drug classes, and applicants, may submit electronic comments or objections and may file written requests for a hearing on this application on or before January 26, 2026. Comments must be submitted through https://www.regulations.gov.
Registration Limited to Research Use
The notice states that, if registered, Irvine Labs' authorization would be limited to bulk manufacture of the listed drug codes for research and development internally and for distribution to its research customers. The registration would not authorize any other activities for those drug codes.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
Previous / Next Documents
Previous: 2025-21186 — Bulk Manufacturer of Controlled Substances Application: Organix Chemistry Solutions, LLC
Organix Chemistry Solutions, LLC wants to become a big-time maker of some powerful controlled substances like LSD and marijuana. If you have thoughts or concerns, you’ve got until January 26, 2026, to speak up or ask for a hearing. This move could shake up who’s allowed to produce these drugs, so keep an eye on the deadline and get involved if you want!
Next: 2025-21188 — Proposal Review; Notice of Meetings
The National Science Foundation (NSF) will hold closed meetings all year to review and decide on funding proposals for research projects. These meetings protect private info and won’t be open to the public, but you can check the NSF website for schedules and updates. This keeps the funding process fair and secure, with no direct cost changes announced.